Cagrilintide
Also Known As: AM833, Cagrilintide AM833, Long-acting amylin analog, Amylin receptor agonist, Calcitonin receptor agonist obesity, Amylin obesity peptide, Pramlintide analog long-acting, Amylin analog cagrilintide, Novo Nordisk amylin, Cagrilintide weekly injection, amylin analog, amylin receptor agonist, cagri
Cagrilintide is a research-grade Long-acting synthetic amylin analog targeting Amylin receptor studied in Weight Loss & Metabolism research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Investigational - In active human clinical trials; not yet approved.
An investigational amylin weight-loss peptide, often paired with semaglutide.
At A Glance
| Category | Weight Loss & Metabolism |
|---|---|
| Compound Class | Long-acting synthetic amylin analog (fatty acid-conjugated for once-weekly dosing) |
| Molecular Target | Amylin receptor (AMY1-3, CTR + RAMP1/2/3 complexes) and calcitonin receptor (CTR); hypothalamic satiety signaling; gastric motility modulation |
| Molecular Weight | 4409.01 Da |
| Amino Acid Sequence | acylated cyclic amylin analog |
| CAS Number | 1415456-99-3 |
| Half-Life | ~1 week (weekly SC, acylated) |
| WADA Status | not_listed |
| Evidence Tier | Investigational |
Mechanism Of Action
It perfectly copies a natural hormone called amylin. It connects to the brain's hunger center and forces it to slow down the emptying of your stomach, keeping you full.
Studied For
- Obesity / overweight
- Type 2 diabetes
- Combination with semaglutide (CagriSema)
- Amylin receptor agonism for satiety
- Caloric intake reduction
- Body weight reduction
- Glucagon suppression
- Gastric emptying delay
- Amylin-mediated satiety signaling
- Cardiometabolic risk reduction
- Insulin sensitivity improvement
- Metabolic syndrome
- weight loss
- satiety
- appetite suppression
- gastric emptying slowing
- obesity
Reported Research Findings
A Phase 2 dose-finding trial showed roughly 10.8 percent weight reduction at 26 weeks with the highest dose versus about 3 percent for placebo; development is most advanced in combination with semaglutide.
Safety And Handling Notes
Predominantly gastrointestinal effects (nausea, vomiting), mild to moderate and dose-dependent; injection-site reactions.
Investigational with no approved indication; long-term safety not established. Research use only.
Regulatory Status
Investigational (Novo Nordisk); not FDA-approved as a single agent. It is the amylin analogue component of CagriSema, which is under FDA review following a December 2025 NDA filing. Not on the WADA 2026 Prohibited List.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.